Order Article Reprints

Banys-Paluchowski M, Loibl S, Witzel I, Mundhenke C, Lederer B, Solbach C, Karn T, Marmé F, Nekljudova V, Schem C, et al. Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial. Cancers. 2019; 11(8):1186. https://doi.org/10.3390/cancers11081186

Banys-Paluchowski, Malgorzata, Sibylle Loibl, Isabell Witzel, Christoph Mundhenke, Bianca Lederer, Christine Solbach, Thomas Karn, Frederik Marmé, Valentina Nekljudova, Christian Schem, and et al. 2019. "Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial" Cancers 11, no. 8: 1186. https://doi.org/10.3390/cancers11081186

Banys-Paluchowski, M., Loibl, S., Witzel, I., Mundhenke, C., Lederer, B., Solbach, C., Karn, T., Marmé, F., Nekljudova, V., Schem, C., Stickeler, E., Willumsen, N., Karsdal, M. A., Untch, M., & Müller, V. (2019). Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial. Cancers, 11(8), 1186. https://doi.org/10.3390/cancers11081186